Cumulative response curves to enhance interpretation of treatment differences on the Self-Esteem and Relationship questionnaire for men with erectile dysfunction

BJU International

Volumn 111, Issue 3 B, 2013, Pages

  Cappelleri, Joseph C ^a   Zou, Kelly H ^a   Bushmakin, Andrew G ^a   Carlsson, Martin O ^a   Symonds, Tara ^b  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

cumulative distribution function; cumulative response curve; erectile dysfunction; responder analysis; Self Esteem And Relationship questionnaire; sildenafil

Indexed keywords

PLACEBO; SILDENAFIL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CUMULATIVE RESPONSE CURVE; ERECTILE DYSFUNCTION; HUMAN; HUMAN RELATION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL PARAMETERS; POST HOC ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SELF ESTEEM; SELF ESTEEM AND RELATIONSHIP QUESTIONNAIRE; SEXUAL SATISFACTION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; DATA INTERPRETATION, STATISTICAL; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; QUESTIONNAIRES; SELF CONCEPT; SULFONES; YOUNG ADULT;

EID: 84874733484     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11489.x     Document Type: Article

References (23)

1. Carson C, Giuliano F, Goldstein I, et al,. The 'effectiveness' scale-therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report. Int J Impot Res 2004; 16: 207-13
2. Cappelleri JC, Althof SE, Siegel RL, Shpilsky A, Bell SS, Duttagupta S,. Development and validation of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction. Int J Impot Res 2004; 16: 30-8
3. O'Leary MP, Althof SE, Cappelleri JC, Crowley A, Sherman N, Duttagupta S,. Self-esteem, confidence and relationship satisfaction of men with erectile dysfunction treated with sildenafil citrate: a multicenter, randomized, parallel group, double-blind, placebo controlled study in the United States. J Urol 2006; 175: 1058-62
4. Cappelleri JC, Althof SE, O'Leary MP, Tseng LJ, the US and International SEAR Study Groups. Analysis of single items on the Self-Esteem And Relationship questionnaire in men treated with sildenafil citrate for erectile dysfunction: results of two double blind, placebo-controlled trials. BJU Int 2008; 101: 861-6
5. Althof SE, O'Leary MP, Cappelleri JC, et al,. Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: results from an international, multi-center, double-blind, placebo-controlled trial. J Sex Med 2006; 3: 521-9
6. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD,. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 163-9
7. Snapinn SM, Jiang Q,. Responder analyses and the assessment of a clinically relevant treatment effect. Trials 2007; 8: 31
8. US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 2009; 74: 65132-3
9. Committee for Medicinal Products for Human Use (CHMP). Guideline on the Choice of the Noninferiority Margin. London: European Medicines Agency, 2005
10. Senn S,. Disappointing dichotomies. Pharma Stat 2003; 2: 239-40
11. Altman DG,. Practical Statistics for Medical Research. Boca Raton, FL: Chapman & Hall/CRC, 1991
12. SAS Institute Inc. SAS/STAT® User's Guide. Version 9.2. Cary, NC: SAS Institute Inc., 2008
13. Cappelleri JC, Althof SE, O'Leary MP, et al,. Clinically meaningful improvement on the Self-Esteem And Relationship questionnaire in men with erectile dysfunction. Qual Life Res 2007; 16: 1203-10
14. Fehnel SE, McLeod LD, Brandman J, et al,. Responsiveness of the Acne-Specific Quality of Life Questionnaire (Acne-QoL) to treatment for acne vulgaris in placebo-controlled clinical trials. Qual Life Res 2002; 11: 809-16
15. Bushmakin AG, Cappelleri JC,. A note on cumulative distribution functions for patient-reported outcomes. PRO Newsletter 2011; 45: 11-2
16. Dubois D, Gilet H, Viala-Danten M, Tack J,. Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation. Neurogastroenterol Motil 2010; 22: e54-63
17. Atkinson AJ Jr, Abernethy DR, Daniels CE, Dedrick RL, Markey SP,. Principles of Clinical Pharmacology. Second Edition. London: Elsevier Inc., 2007
18. O'Leary MP, Rhodes T, Girman CJ, et al,. Distribution of the Brief Male Sexual Inventory in community men. Int J Impot Res 2003; 15: 185-91
19. Coyne K, Revicki D, Hunt T, et al,. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002; 11: 563-74
20. Coyne KS, Matza LS, Thompson CL,. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 2005; 14: 849-55
21. Coyne K, Matza L, Thomspon C, Kopp Z, Khullar V,. Determining the importance of change in the Overactive Bladder Questionnaire. J Urol 2006; 176: 627-32
22. Wei J, Dunn R, Litwin M, Sandler H, Sanda M,. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899-905
23. Chang P, Szymanski KM, Dunn RL, et al,. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol 2011; 186: 865-72